The recurrence rate of adenocarcinoma in situ is less than 5% and most patients can achieve clinical cure after surgery. Adenocarcinoma in situ of the cervix belongs to the very early stage of cervical cancer, and since the lesion is limited and has not spread, the risk of recurrence and metastasis is very low, and the clinical research data report that the five-year survival rate of the patients is more than 95%, and the risk of recurrence is less than 5%. Because of the low risk of recurrence of adenocarcinoma in situ after surgery, most patients do not need to be given adjuvant chemotherapy or radiotherapy after surgery. However, since it is still a malignant tumor, regular checkups should be conducted to monitor the changes of the disease and to detect possible recurrence or metastasis in a timely manner.